Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006061
Filing Date
2021-05-06
Accepted
2021-05-06 07:06:32
Documents
64
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20210331x10q.htm   iXBRL 10-Q 1570631
2 EX-31.1 tmb-20210331xex31d1.htm EX-31.1 7123
3 EX-31.2 tmb-20210331xex31d2.htm EX-31.2 7113
4 EX-32.1 tmb-20210331xex32d1.htm EX-32.1 9198
5 GRAPHIC tmb-20210331x10q001.jpg GRAPHIC 18164
  Complete submission text file 0001558370-21-006061.txt   5645554

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20210331.xsd EX-101.SCH 45939
7 EX-101.CAL tmb-20210331_cal.xml EX-101.CAL 36867
8 EX-101.DEF tmb-20210331_def.xml EX-101.DEF 128215
9 EX-101.LAB tmb-20210331_lab.xml EX-101.LAB 364143
10 EX-101.PRE tmb-20210331_pre.xml EX-101.PRE 267448
11 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20210331x10q_htm.xml XML 910308
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37410 | Film No.: 21895735
SIC: 2834 Pharmaceutical Preparations